Gene Therapies for neurodegenerative
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
9
NCT06064890
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 30, 2023
Completion: Oct 31, 2030
Loading map...